Cargando…

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures

Despite the success of immunotherapy using checkpoint blockade, many patients with solid tumors remain refractory to these treatments. In human cancer, the experimental options to investigate the specific effects of antibodies blocking inhibitory receptors are limited and it is still unclear which c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gestermann, Nicolas, Saugy, Damien, Martignier, Christophe, Tillé, Laure, Fuertes Marraco, Silvia A., Zettl, Markus, Tirapu, Iñigo, Speiser, Daniel E., Verdeil, Grégory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422827/ https://www.ncbi.nlm.nih.gov/pubmed/32850194 http://dx.doi.org/10.1080/2162402X.2020.1736792

Ejemplares similares

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses
por: Zettl, Markus, et al.
Publicado: (2022)

Development of a LAG-3 immunohistochemistry assay for melanoma
por: Johnson, Lori, et al.
Publicado: (2023)

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
por: Huuhtanen, Jani, et al.
Publicado: (2023)

Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance
por: Wei, Yiming, et al.
Publicado: (2022)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Inhibitory Receptors Beyond T Cell Exhaustion
por: Fuertes Marraco, Silvia A., et al.
Publicado: (2015)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

LAG3’s Enigmatic Mechanism of Action
por: Graydon, Colin G., et al.
Publicado: (2021)

Overcoming the LAG3 phase problem
por: Petersen, Jan, et al.
Publicado: (2022)

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
por: Schöffski, Patrick, et al.
Publicado: (2022)

Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020)

T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity
por: Cemerski, Saso, et al.
Publicado: (2015)

The extent of metalloproteinase-mediated LAG3 cleavage limits the efficacy of PD1 blockade
por: Andrews, Lawrence P, et al.
Publicado: (2015)

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
por: Lichtenegger, Felix S., et al.
Publicado: (2018)

Association of LAG3 genetic variation with an increased risk of PD in Chinese female population
por: Guo, Wenyuan, et al.
Publicado: (2019)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
por: Jiang, Haiping, et al.
Publicado: (2021)

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2020)

Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients
por: Murray, Timothy, et al.
Publicado: (2016)

LAG-3 expression in the inflammatory microenvironment of glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Clinical landscape of LAG-3-targeted therapy
por: Chocarro, L., et al.
Publicado: (2022)

LAG3 in gastric cancer: it’s complicated
por: Ulase, Dita, et al.
Publicado: (2023)

LAG3 and Its Ligands Show Increased Expression in High-Risk Uveal Melanoma
por: Souri, Zahra, et al.
Publicado: (2021)

Mathematical modeling identifies LAG3 and HAVCR2 as biomarkers of T cell exhaustion in melanoma
por: Beck, Richard J., et al.
Publicado: (2023)

ScanLag: High-throughput Quantification of Colony Growth and Lag Time
por: Levin-Reisman, Irit, et al.
Publicado: (2014)

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
por: Okazaki, Taku, et al.
Publicado: (2011)

Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer
por: Sobottka, Bettina, et al.
Publicado: (2021)

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
por: Tobin, Joshua W. D., et al.
Publicado: (2021)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
por: Shi, Ning, et al.
Publicado: (2022)

Jet Lag in Athletes
por: Lee, Aaron, et al.
Publicado: (2012)

Is Prosthetic Dentistry Lagging?: No
por: Trueman, William H.
Publicado: (1894)

Taking the Lag out of Jet Lag through Model-Based Schedule Design
por: Dean, Dennis A., et al.
Publicado: (2009)

Modeling exposure–lag–response associations with distributed lag non-linear models
por: Gasparrini, Antonio
Publicado: (2014)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials
por: Zhao, Bai-Wei, et al.
Publicado: (2022)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

Roles, function and relevance of LAG3 in HIV infection
por: Graydon, Colin G., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nqukl5mh57jh44ocaalecbr8qq